Xcout Intel
NBE-Therapeutics
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Subscribe to see NBE-Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NBE-Therapeutics at a glance
NBE-Therapeutics is a biotechnology company headquartered in Switzerland. It has raised at least $23.8M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $20.7M in November 2016. Xcout tracks 3 named people at NBE-Therapeutics, including Olof Prause (Chief Operating Officer).
NBE-Therapeutics leadership
- Olof PrauseChief Operating Officer
- Andy BrossChief Financial Officer
- Carl DeutschChief Scientific Officer
NBE-Therapeutics funding rounds
At least $23.8M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $20.7M | — | |
| Series A | $3.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
NBE-Therapeutics competitors
A few of NBE-Therapeutics's closest competitors — see the full list of competitors and alternatives →
Tubulis is a biotechnology organization headquartered in Munich that generates uniquely matched antibody-drug conjugates with superior biophysical properties.
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
AbTx (Antibody for Therapy) is a preclinical-stage biotechnology company headquartered in Dijon, France. The firm designs personalized medicine biotherapies in oncology based on antibody-drug conjugates (ADCs) to treat incurable cancers.
Get NBE-Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on NBE-Therapeutics in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access